Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
NCT01357616
First received: May 18, 2011
Last updated: March 13, 2014
Last verified: March 2014
  Purpose

The purpose of this study was to compare the intraocular pressure (IOP)-lowering efficacy and safety of AZARGA™ (Brinzolamide 1%/Timolol 0.5% Ophthalmic Suspension), dosed twice daily versus AZOPT® (Brinzolamide 1% Ophthalmic Suspension) and Timolol 0.5% Ophthalmic Solution, each dosed twice daily, in Chinese patients with open-angle glaucoma or ocular hypertension who were insufficiently responsive to monotherapy.


Condition Intervention Phase
Open-Angle Glaucoma
Ocular Hypertension
Drug: Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension
Drug: Brinzolamide 1% ophthalmic suspension
Drug: Timolol 0.5% ophthalmic solution
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Comparison of Efficacy and Safety of Brinzolamide/Timolol Fixed Combination (AZARGA™) vs Brinzolamide (AZOPT®) and Timolol in Chinese Subjects With Open-Angle Glaucoma or Ocular Hypertension

Resource links provided by NLM:


Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Mean Diurnal IOP Change From Baseline at Week 8 [ Time Frame: Baseline, Week 8 ] [ Designated as safety issue: No ]
    Mean diurnal IOP change from baseline at Week 8 (ie, the subject IOP change from baseline averaged over the 9 AM, 11AM and 5 PM time points at Week 8) was measured by Goldmann applanation tonometry. One eye from each subject was chosen as the study eye, and only data for the study eye were used for the efficacy analysis. A higher IOP (fluid pressure inside the eye) can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). A more negative change indicates a greater improvement..


Secondary Outcome Measures:
  • Mean IOP Change From Baseline at 9 AM [ Time Frame: Baseline, Up to Week 8 ] [ Designated as safety issue: No ]
    Mean IOP change from baseline at 9 AM was measured by Goldmann applanation tonometry. One eye from each subject was chosen as the study eye, and only data for the study eye were used for the efficacy analysis. A higher IOP (fluid pressure inside the eye) can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). A more negative change indicates a greater improvement.

  • Mean IOP Change From Baseline at 11 AM [ Time Frame: Baseline, Up to Week 8 ] [ Designated as safety issue: No ]
    Mean IOP change from baseline at 11 AM was measured by Goldmann applanation tonometry. One eye from each subject was chosen as the study eye, and only data for the study eye were used for the efficacy analysis. A higher IOP (fluid pressure inside the eye) can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). A more negative change indicates a greater improvement.

  • Mean IOP Change From Baseline (5 PM) at Week 8 [ Time Frame: Baseline, Week 8 ] [ Designated as safety issue: No ]
    Mean IOP change from baseline (5 PM) at Week 8 was measured by Goldmann applanation tonometry. One eye from each subject was chosen as the study eye, and only data for the study eye were used for the efficacy analysis. A higher IOP (fluid pressure inside the eye) can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). A more negative change indicates a greater improvement.


Enrollment: 328
Study Start Date: November 2010
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AZARGA
Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, 1 drop in the affected eye(s) dosed twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential safety issue to the patient in the opinion of the Investigator.
Drug: Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension
Other Name: AZARGA™
Active Comparator: AZOPT + Timolol
Brinzolamide 1% ophthalmic suspension, 1 drop instilled in the affected eye(s), followed by Timolol 0.5% ophthalmic solution, 1 drop instilled in the affected eye(s). Approximately 10 minutes separated the 2 instillations. The study drugs were instilled twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential safety issue to the patient in the opinion of the Investigator.
Drug: Brinzolamide 1% ophthalmic suspension
Other Name: AZOPT®
Drug: Timolol 0.5% ophthalmic solution
Other Name: TIMOLOL

Detailed Description:

The study consisted of 2 sequential phases. Phase I was the Screening/Eligibility Phase, with a Screening Visit followed by an Eligibility Visit. Phase II was the treatment phase and included Week 1, Week 2, Week 4, and Week 8 visits. Eligible subjects were randomized in a 1:1 ratio to receive Brinzolamide 1%/Timolol 0.5% or Brinzolamide 1% plus Timolol 0.5% two times a day for 8 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with open angle glaucoma and/or ocular hypertension and not sufficiently responsive to monotherapy.
  • Meet qualifying IOP criteria in at least 1 eye, including 21-35 mmHg at the Eligibility visit.
  • Willing to sign an Informed Consent form.
  • Contact lens wearer who is willing to remove lenses before instillation of study medication and wait a minimum of 15 minutes following drug instillation before re-inserting the lenses.
  • Able to discontinue use of current IOP-lowering medications per the minimum washout period.
  • Other protocol-specific inclusion criteria may apply.

Exclusion Criteria:

  • Women of childbearing potential if pregnant, test positive for pregnancy at Screening/Enrollment visit, breastfeeding, or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.
  • Diagnosed with any form of glaucoma other than open-angle glaucoma and/or ocular hypertension.
  • Diagnosed with severe central visual field loss in either eye.
  • History of chronic, recurrent, or severe ocular infection, inflammatory eye disease in either eye.
  • History of ocular trauma within the past 6 months in either eye.
  • Current ocular infection or ocular inflammation within the past 3 months in either eye.
  • Ocular laser surgery within the past 3 months.
  • Intraocular surgery within the past 3 months.
  • Best-corrected visual acuity score worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen, 0.60 logMAR or 0.25 decimal).
  • History of, or current clinically relevant or progressive retinal disease in either eye.
  • History of, or current other severe ocular pathology (including severe dry eye) in either eye, that would preclude the administration of a topical carbonic anhydrase inhibitor (CAI) or beta-blocker.
  • Any abnormality preventing reliable applanation tonometry.
  • History of, or current condition or disease that would preclude the safe administration of a topical beta blocker or topical beta-adrenergic blocking agent.
  • History of spontaneous or current hypoglycemia or uncontrolled diabetes.
  • History of severe or serious hypersensitivity to CAIs, beta-blockers, or to any components of the study medication.
  • Less than 30 days stable dosing regimen before the Screening Visit of any medications or substances administered by any route and used on a chronic basis that may have affected IOP.
  • Recent use of high-dose salicylate therapy.
  • Anticipated use of any additional topical or systemic ocular hypotensive medication during the study.
  • Not safely able to discontinue all glucocorticoid medications administered by any route.
  • Currently on therapy or have been on therapy with another investigational agent within 30 days prior to the Screening Visit.
  • History of, or current evidence of severe illness or any other conditions which would, in the opinion of the Investigator, make the subject unsuitable for the study.
  • Other protocol-specific exclusion criteria may apply.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01357616

Sponsors and Collaborators
Alcon Research
Investigators
Study Director: Mandy Ye, MS Alcon Research
  More Information

No publications provided

Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT01357616     History of Changes
Other Study ID Numbers: C-08-076
Study First Received: May 18, 2011
Results First Received: January 30, 2014
Last Updated: March 13, 2014
Health Authority: China: Food and Drug Administration
China: Ethics Committee

Keywords provided by Alcon Research:
Glaucoma
Open-angle glaucoma
Ocular hypertension
OAG
OH

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Hypertension
Ocular Hypertension
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
Timolol
Brinzolamide
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Antihypertensive Agents
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on April 20, 2014